Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
All outcomes

Feedback
Home   COVID-19 treatment studies for Bebtelovimab  COVID-19 treatment studies for Bebtelovimab  C19 studies: Bebtelovimab  Bebtelovimab   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 bebtelovimab studies
0 0.5 1 1.5+ All studies -151% 1 380 Improvement, Studies, Patients Relative Risk Mortality -151% 1 380 Hospitalization -27% 1 380 Viral clearance 36% 1 380 RCTs -151% 1 380 Early -151% 1 380 Bebtelovimab for COVID-19 c19early.com/bt Aug 2022 Favorsbebtelovimab Favorscontrol
0 0.5 1 1.5+ ALL STUDIES MORTALITY HOSPITALIZATION VIRAL CLEARANCE RCTS All Early Bebtelovimab for COVID-19 C19EARLY.COM/BT AUG 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement All studies -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement 1 bebtelovimab COVID-19 study c19early.com/bt Aug 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] 1/252 0/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement All studies -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement 1 bebtelovimab COVID-19 mortality result c19early.com/bt Aug 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.79 Early treatment -27% 1.27 [0.25-6.46] 5/252 2/128 -27% improvement All studies -27% 1.27 [0.25-6.46] 5/252 2/128 -27% improvement 1 bebtelovimab COVID-19 hospitalization result c19early.com/bt Aug 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.79 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement All studies -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement 1 bebtelovimab COVID-19 serious outcome c19early.com/bt Aug 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.066 Early treatment 36% 0.64 [0.40-1.03] 33/252 26/128 36% improvement All studies 36% 0.64 [0.40-1.03] 33/252 26/128 36% improvement 1 bebtelovimab COVID-19 viral clearance result c19early.com/bt Aug 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.066 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement All studies -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement 1 bebtelovimab COVID-19 Randomized Controlled Trials c19early.com/bt Aug 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] 1/252 0/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement All studies -151% 2.51 [0.10-61.1] 1/252 0/128 -151% improvement 1 bebtelovimab COVID-19 RCT mortality result c19early.com/bt Aug 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Lilly (RCT) -201% 3.01 [0.12-73.2] death 1/127 0/128 Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Lilly (RCT) -51% 1.51 [0.26-8.90] hosp. 3/127 2/128 Lilly (RCT) -2% 1.02 [0.15-7.16] hosp. 2/125 2/128 Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Lilly (RCT) 38% 0.62 [0.35-1.10] viral+ 16/127 26/128 Lilly (RCT) 33% 0.67 [0.38-1.17] viral+ 17/125 26/128 bebtelovimab COVID-19 outcomes c19early.com/bt Aug 2022 Favors bebtelovimab Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit